Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Frequently asked questions
What sector does Regentis Biomaterials Ltd. (RGNT) operate in?
Regentis Biomaterials Ltd. belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is Regentis Biomaterials Ltd. (RGNT) current stock price?
As of the latest data, Regentis Biomaterials Ltd. stock price is $1.26, with a previous close of $1.28. Regentis Biomaterials Ltd. lost -$0.02 in the last trading session, representing a -1.56% loss.
What is Regentis Biomaterials Ltd. (RGNT) current market capitalization?
Regentis Biomaterials Ltd. market cap is approximately 8.85 million.
What is Regentis Biomaterials Ltd. (RGNT) Earnings Per Share (EPS)?
The trailing EPS is -$23.94.
Does Regentis Biomaterials Ltd. (RGNT) pay dividends?
No. Regentis Biomaterials Ltd. does not pay a dividend.
What is Regentis Biomaterials Ltd. (RGNT) beta (volatility) score?
Regentis Biomaterials Ltd. has a beta of -0.305, indicating lower volatility than the overall market.